Skip to Main Content

Paper Details

Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.
Clin Gastroenterol Hepatol
17
2022
Author NameAffiliation
Siddharth SinghUniversity of California San Diego
Parambir S DulaiUniversity of California San Diego
Nilay D ShahRobert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Department of Health Services Research
William J SandbornUniversity of California San Diego
  • 1 - 4

Datasets

Release 1.2